RESONIUM CALCIUM 999 MG
CALCIUM POLYSTYRENE SULFONATE : 999 MG · DIN 02017741 · SANOFI-AVENTIS CANADA INC
Health Canada status: MARKETED
What is RESONIUM CALCIUM?
RESONIUM CALCIUM 999 MG contains CALCIUM POLYSTYRENE SULFONATE : 999 MG. It is listed in the Health Canada Drug Product Database under DIN 02017741, held by SANOFI-AVENTIS CANADA INC, supplied as POWDER FOR SOLUTION for ORAL ; RECTAL administration. Health Canada currently lists it as marketed, status dated 18-Jul-2008. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is RESONIUM CALCIUM used for?
RESONIUM CALCIUM (calcium polystyrene sulfonate) is indicated in patients with hyperkalemia associated with anuria or severe oliguria. It reduces serum levels of potassium and removes excess potassium from the body. RESONIUM CALCIUM is indicated in all states of hyperkalemia due to acute and chronic renal failure; examples include use following abortion, complicated labor, incompatible blood transfusion, crush injury, prostatectomy, severe burns, surgical shock, and in cases of severe glomerulonephritis and pyelonephritis. RESONIUM CALCIUM can also be useful in patients requiring dialysis. Serum potassium levels in acute renal failure often reach dangerous heights before a rise in blood urea indicates the need for hemodialysis. RESONIUM CALCIUM can be used to reduce these potassium levels and thereby postpone the need for the use of the artificial kidney machine until other causes make it necessary. Patients on regular hemodialysis therapy may develop shunt difficulties and under dialysis occurs, resulting in serious hyperkalemia. In these circumstances it is advisable to give RESONIUM CALCIUM to control hyperkalemia during the period of under dialysis. When patients on routine hemodialysis present a dietary management problem and tend towards hyperkalemia, RESONIUM CALCIUM can be used to control blood potassium levels. Similarly, patients on prolonged peritoneal dialysis may develop intermittent hyperkalemia after a few weeks, possibly due to dietary problems. These patients also can be satisfactorily controlled with RESONIUM CALCIUM.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02017741 |
|---|---|
| Brand name | RESONIUM CALCIUM |
| Generic / active ingredient | CALCIUM POLYSTYRENE SULFONATE : 999 MG |
| Manufacturer | SANOFI-AVENTIS CANADA INC |
| Strength | 999 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | ORAL ; RECTAL |
| Schedule | Ethical |
| ATC code | V03AE01 POLYSTYRENE SULPHONATE |
| AHFS class | 40:18.18 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 18-Jul-2008 |
| Original market date | 1979-12-31 00:00:00 |
How is it stored and handled?
Store at room temperature (15 to 30 °C).
How is it supplied?
300 g jars, with a 15 g plastic measure
What can be used instead?
Other Canadian products sharing ATC code V03AE01 POLYSTYRENE SULPHONATE. 7 of 16 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP SODIUM POLYSTYRENE SULFONATE | 1 G | POWDER FOR SUSPENSION | JAMP PHARMA CORPORATION | MARKETED | DIN 02497557 |
| KAYEXALATE | 1 G | POWDER FOR SUSPENSION | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02026961 |
| ODAN-SODIUM POLYSTYRENE SULFONATE | 1 G | POWDER FOR SUSPENSION | ODAN LABORATORIES LTD | MARKETED | DIN 02473941 |
| ODAN-SODIUM POLYSTYRENE SULFONATE | 250 MG | SUSPENSION | ODAN LABORATORIES LTD | MARKETED | DIN 02473968 |
| SOLYSTAT | 1 G | POWDER FOR SUSPENSION | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 00755338 |
| SOLYSTAT | 250 MG | SUSPENSION | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | DIN 00769541 |
| JAMP CALCIUM POLYSTYRENE SULFONATE | 999 MG | POWDER FOR SUSPENSION | JAMP PHARMA CORPORATION | DORMANT | DIN 02502631 |
| K-EXIT POUDRE | 100 % | POWDER FOR SOLUTION | OMEGA LABORATORIES LIMITED | CANCELLED POST MARKET | DIN 00765252 |
| PHL-SODIUM POLYSTYRENE SULFONATE ORAL SUSPENSION | 250 MG | SUSPENSION | PHARMEL INC | CANCELLED POST MARKET | DIN 02261650 |
| PHL-SODIUM POLYSTYRENE SULFONATE POWDER | 94.3 MG | POWDER | PHARMEL INC | CANCELLED POST MARKET | DIN 02261677 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.